NIRST and ICG-based Perfusion Imaging in Acute Compartment Syndrome

Dartmouth-Hitchcock Medical Center15 enrolled

Overview

This is a prospective observational study of patients with suspected Acute Compartment Syndrome. The primary objective of this work is to determine whether intensity changes associated with the NIRST signal, reflecting oxy- and deoxy-hemaglobin and water concentrations or ICG fluorescence signal, reflecting tissue perfusion, can be associated with development of Acute Compartment Syndrome and identification of at-risk soft tissue and muscle.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Compartment Syndromes Compartment Syndrome of Lower Leg Compartment Syndrome of Forearm

Interventions

Lower extremity and/or upper extremity surgeryPROCEDURE

Lower extremity and/or upper extremity surgery

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age 18 years or older * Clinical suspicion of acute compartment syndrome based on orthopaedic provider assessment. Clinical suspicion would be based upon the presence of one or more of these findings: * Pain out of proportion to visible findings * Escalating doses of pain medication * Pain with passive stretch of toes and/or fingers * Pallor, paresthesias, pulselessness * Tense soft tissues * High energy tibia or forearm fracture * Provision of informed consent Exclusion Criteria: * History of allergy to ICG and/or iodine * Pregnant women or nursing mothers * Any patient with an open wound for whom NIRST device cannot be applied \>4cm from the open wound will be excluded from NIRST imaging.

Locations (1)

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Outcomes

Primary Outcomes

Association of NIRST or ICG measurements with development of ACS

The primary objective of this work is to determine whether total hemoglobin, oxygen saturation and water content imaged by NIRST or ICG fluorescence signal, reflecting tissue perfusion, can be associated with development of Acute Compartment Syndrome and identification of at-risk soft tissue and muscle.

Time frame: 36 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.